Quintrio
Home

SERVICES-PREPACKAGED SOFTWARE

Veeva Systems Inc.

VEEV

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Last trade $293.51
Day change -$5.775 (-1.93%)
Day range $291.12 – $300.86
Volume 647,870
Market cap $48.46B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$48.46B
Price / earnings
47.75×
Price / book
6.52×
Price / sales
14.01×
EV / sales
13.49×
EV / EBITDA
43.38×

Profitability

Earnings per share
$6.27
Return on assets
11.2%
Return on equity
13.66%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
5.46×
Quick ratio
5.46×
Cash ratio
1.24×

Cash flow

Price / cash flow
29.09×
Price / free cash flow
29.39×
Free cash flow
$1.65B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for VEEV, quarterly periods
Line itemQ2 FY2027 Jul 31, 2026Q1 FY2027 Apr 30, 2026Q4 FY2026 Jan 31, 2026Q3 FY2026 Oct 31, 2025Q2 FY2026 Jul 31, 2025Q1 FY2026 Apr 30, 2025Q4 FY2025 Jan 31, 2025Q3 FY2025 Oct 31, 2024
Revenue$927.96M$882.95M$835.95M$811.24M$789.08M$759.04M$720.89M$699.21M
Cost of revenue$232.01M$220.92M$213.48M$199.47M$195.25M$173.82M$180.99M$174.39M
Gross profit$695.95M$662.02M$622.47M$611.77M$593.83M$585.22M$539.9M$524.82M
Selling, general and administrative$198.02M$180.59M$177.81M$179.04M$205.24M$167.45M$169.95M$171.05M
Research and development$222.92M$208.32M$198.79M$191.88M$192.68M$184.03M$181.53M$172.41M
Total operating expenses$420.93M$388.91M$376.6M$370.92M$397.92M$351.49M$351.47M$343.47M
Operating income$275.02M$273.11M$245.88M$240.85M$195.91M$233.73M$188.42M$181.35M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes$349.53M$347.53M$317.54M$312.79M$265.36M$298.82M$245.13M$242.29M
Income taxes$76.1M$86.59M$73.33M$76.58M$65.06M$70.63M$49.51M$56.48M
Net income$273.43M$260.94M$244.2M$236.2M$200.31M$228.19M$195.63M$185.81M
Net income attributable to common shareholders$273.43M$260.94M$244.2M$236.2M$200.31M$228.19M$195.63M$185.81M
EBITDA$285.89M$284.7M$254.19M$250.56M$206.03M$243.55M$198.36M$191.29M
Basic earnings per share$1.68$1.60$1.49$1.44$1.23$1.40$1.20$1.15
Diluted earnings per share$1.66$1.57$1.48$1.40$1.19$1.37$1.17$1.13

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates

Vivos Therapeutics reported a Q3 loss of $0.07 per share, beating consensus estimates of $0.30 loss by 76.67%. Revenue came in at $6.41 million, surpassing estimates by 17.15%, though down from $6.78 million year-ago. The stock has declined 95.2% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.

Zacks Investment Research

Bullfrog AI Holdings Inc. (BFRG) Reports Q3 Loss, Lags Revenue Estimates

Bullfrog AI Holdings Inc. (BFRG) reported a Q3 loss of $0.11 per share, missing consensus estimates of $0.09 loss by 22.22%. Revenue came in at $0.06 million, missing estimates by 71.1%. The stock has declined 37.4% year-to-date and received a Zacks Rank #3 (Hold) rating, expected to perform in line with the market.

Zacks Investment Research

NeuroPace, Inc. (NPCE) Reports Q3 Loss, Misses Revenue Estimates

NeuroPace (NPCE) reported a quarterly loss of $0.03 per share, beating consensus estimates of $0.06 loss by 50%, but missed revenue expectations with $23.1 million versus the estimated $26.9 million. The company has underperformed the S&P 500 by 30.2% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know

Veeva Systems, a cloud-based software provider for the life sciences industry, has outperformed the broader market over the past month with a +2.5% return. The company shows strong earnings growth expectations of +13.8% for the current fiscal year and +10.2% for the next year, with a consistent track record of beating consensus estimates. However, the stock is rated Zacks Rank #3 (Hold) and trades at a premium valuation (Grade D) compared to peers, suggesting it may perform in line with the broader market in the near term.

GlobeNewswire Inc.

Devia Emerges from Stealth with an Agentic AI for GxP Pharma Quality Management

Devia, an agentic AI platform spun out from Visium, officially launched to help biopharma companies, CDMOs, and CROs manage pharmaceutical deviations. The platform automates deviation investigation workflows from initial report through root cause analysis and CAPA, with built-in traceability for regulatory compliance. After a year of pilot testing with quality teams, Devia claims to have halved investigation time while integrating with existing validated systems like TrackWise and Veeva Vault QMS.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.